Baillie Gifford & CO Guardant Health, Inc. Transaction History
Baillie Gifford & CO
- $128 Billion
- Q3 2025
A detailed history of Baillie Gifford & CO transactions in Guardant Health, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 5,127,692 shares of GH stock, worth $477 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
5,127,692
Previous 4,809,786
6.61%
Holding current value
$477 Million
Previous $250 Million
28.0%
% of portfolio
0.25%
Previous 0.2%
Shares
8 transactions
Others Institutions Holding GH
# of Institutions
425Shares Held
127MCall Options Held
1.51MPut Options Held
2.35M-
Vanguard Group Inc Valley Forge, PA12.2MShares$1.13 Billion0.01% of portfolio
-
Black Rock Inc. New York, NY11.2MShares$1.05 Billion0.01% of portfolio
-
Capital International Investors Los Angeles, CA4.98MShares$463 Million0.05% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.25MShares$395 Million7.85% of portfolio
-
Invesco Ltd. Atlanta, GA3.56MShares$331 Million0.03% of portfolio
About Guardant Health, Inc.
- Ticker GH
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 102,220,000
- Market Cap $9.51B
- Description
- Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...